|
MBCI is a biotechnology company whose vision is to change the
perception of cancer as a largely incurable disease.
MBCI's
primary mission is to develop novel diagnostics for the
early detection of cancer when the disease is still
localized and treatable, and where the chances for cure
are greater than 90 percent!
I would like everyone to watch this video of
MBCI's CEO talk about the Company-
http://www.mabcure.com/about_video.html
Most ?killer? cancers such as ovarian, colorectal, breast, lung,
and prostate carcinomas owe their lethality to late
diagnosis when the disease has already spread beyond its
original site.
According to the American Cancer Society, most patients
have more than a 90% chance of 5-year survival when
cancer is detected early. The only example of an
effective early detection test is the PAP smear which
has brought about a significant reduction in cervical
cancer morbidity and mortality. However, similar methods
for screening and diagnosing most cancers in their early
stage remain elusive.
MBCI is a company whose vision is to change the perception of
cancer as a largely incurable disease. MabCure's
scientists believe that the key to early detection of
cancer by antibodies lies in their ability to identify
putative tumor markers or tumor-specific antigens (TSA),
present on the surface of these cells. Using its
proprietary technology,
MBCI
has created unique and highly specific Mabs against
several cancers (e.g.
ovarian and prostate carcinomas) which could potentially
identify these diseases in their earliest stage! The
development of unique and highly specific diagnostic
tests could lead to far earlier diagnoses than has ever
been possible which, in turn, will bring curing cancers
closer to clinical reality.
Beyond the initial focus on developing diagnostic
tests, MBCI's
strategic plan calls for the application of its
proprietary cancer-specific Mabs in three additional
areas:
-
The imaging of cancer
-
Immunotherapy of cancer
-
Discovery of novel cancer markers (tumor specific antigens), which
can lead to the development of potent anti-cancer
drugs.
In summary,
MBCI's first goal is the development of
simple diagnostic tests for the early detection of
ovarian, prostate, colorectal and breast carcinomas.
Each test will be based upon specific Mabs against a
given cancer which should be able to detect unique
cancer markers in the blood, urine or other body fluids.
Identifying the presence of disease before it
disseminates beyond its original site should lead to a
90% cure rate of these cancer patients.
Let me tell you a little about their technology.
MBCI is a biotechnology company using a "re-engineered"
Hybridoma methodology to create monoclonal antibodies (Mabs)
for the detection of cancer at an early stage, where the
cure rates are greater than 90%.
MBCI
has already generated highly specific Mabs against three
human malignancies: melanoma, ovarian, and prostate
cancers!
Unlike all other commercially available
"anti-cancer" antibodies, MabCures Mabs uniquely target
only cancer cells. These Mabs will first serve for the
detection of early stage cancers and later as candidates
for cancer imaging and for the development of
cancer-specific drugs devoid of toxicity.
There
are no blood tests or useful imaging methods that can
adequately and routinely detect most types of cancers
when they are at their earliest and most curable stage.
MBCI
has the answer to this problem!
Monoclonal
antibodies (MAbs) are one of the most useful
biomolecules ever discovered!
From my understanding, this all comes
about by taking a piece of the persons cancer and then
they clone it and form antibodies against the cancer to
help the body "recognize" the cancer and fight the
diseased cells. They then inject the antibodies and this
in theory then gives the body a chance to kill the
cancer cells using its own immune system. This has
started to become a HUGE breakthrough and story across
the world and
MBCI is position perfectly to capitalize on it!
The
challenge of producing antibodies against specific
cancer antigens has eluded scientists for many decades.
Modern technologies for designing antibodies against a
known disease require both the identification and
availability of the antigens which characterize the
disease. The putative tumor-specific antigens (TSA),
presumed to exist on cancer cells, have eluded
identification, thus making the generation of antibodies
against them through current technologies virtually
impossible.
Classic Hybridoma technology is based on
the generation of immortal hybrid cells (hybridoma),
which follows the fusion of antibody-producing B-cells
with myeloma tumor cells. Each hybridoma continuously
manufactures a single type of (monoclonal)
antibody. MBCI
has "re-engineered"
the classic hybridoma technology into a highly efficient
and optimized one, overcoming the inherent limitations
of the former, yet exploits its benefits!
MBCI
hybridoma technology exhibits several
important advantages over competing technologies:
- Prior identity of cancer antigen(s) is
not required for generating Mabs against these antigens.
MBCI's
approach to creating anti-cancer Mabs is unbiased and
enhances the discovery of new cancer markers.
- Antigens are preserved in their natural
conformations; the resulting Mabs are able to better
recognize and bind more selectively to tumor cells.
- Unlimited quantities of antibodies
produced against a selected cancer target. A large
number of antibodies is the key factor for obtaining an
antibody repertoire which would exhibit both tumor
specificity and tumor "universality".
MBCI
has successfully generated hybridoma libraries for three
different cancers that produce, respectively, antibodies
to melanoma, to an aggressive form of prostate cancer
and to ovarian carcinoma. These antibodies have been
shown to be specific and "universal" to each cancer
respectively, i.e.
they recognize every cancer from different individuals
having that particular disease and do not react with any
normal antigen tested so far. These Mabs are the first
candidates for the development of novel diagnostic
tools, imaging agents and drugs to treat the
corresponding cancers.
MBCI's Market Potential and Opportunity
is Unbelievable!
MBCI is already starting to get tremendous exposure and
publicity. MBCI
has already been featured in the September issue of
GEN (Genetic
Engineering & Biotechnology News). You
can read the article here-
http://www.genengnews.com/articles/chitem.aspx?aid=3022 It
has also been featured in the BioWorld?
Today, biotech?s most respected news source for
over seventeen years and the Biotechnology Focus,
Canada's oldest and most successful magazine serving the
Canadian life science industry! Check it out -
http://www.bioscienceworld.ca/TumourSpecific%20MarkersTheHolyGrailofCancerDiagnostics
Start your due diligence right away on
MBCI
and get ready for another HUGE winner to be added to our
track record! Don't miss out on Monday!
|
